Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
-1.63 (-0.54%)
Real-time:   1:21PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 295.03 - 301.99
52 week 265.00 - 480.18
Open 297.72
Vol / Avg. 848,281.00/3.34M
Mkt cap 70.88B
P/E 20.30
Div/yield     -
EPS 14.78
Shares 235.17M
Beta 0.93
Inst. own 92%
Oct 20, 2015
Q3 2015 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 26, 2015
Iraqi Islamic Bank for Investment and Development Annual Shareholders Meeting
Jul 24, 2015
Q2 2015 Biogen Inc Earnings Release
Jul 24, 2015
Q2 2015 Biogen Inc Earnings Call
Jun 12, 2015
Biogen Idec Inc Annual Shareholders Meeting (Estimated)
Jun 10, 2015
Biogen Inc Annual Shareholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 35.87% 30.47%
Operating margin 47.58% 40.94%
EBITD margin - 47.46%
Return on average assets 23.32% 22.59%
Return on average equity 30.69% 30.21%
Employees 7,550 -
CDP Score - 81 C


225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 52
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 60
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology and Business Solutions
Age: 52
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 57
Bio & Compensation  - Reuters